Nov 19 (Reuters) - Alzamend Neuro Inc :
* ALZAMEND NEURO ANNOUNCES FULL DATA SET FROM ITS NONCLINICAL STUDY: COMPARING BRAIN AND PLASMA LITHIUM EXPOSURES BETWEEN AL001 AND LITHIUM CARBONATE IN ALZHEIMER’S TRANSGENIC MICE
* ALZAMEND NEURO INC: AT A LOW DOSE, AL001 EVIDENCED CONSISTENTLY HIGHER LITHIUM CONCENTRATIONS THAN LITHIUM CARBONATE WITHIN CRITICAL BRAIN REGIONS
* ALZAMEND NEURO INC: BOTH TREATMENTS HAD NO NEGATIVE IMPACT ON MICE'S BODY WEIGHT OR CLINICAL SIGNS DURING TREATMENT PERIOD
* ALZAMEND NEURO INC: AL001 SHOWED LOWER PLASMA LITHIUM LEVELS THAN LITHIUM CARBONATE, REDUCING RISK OF ADVERSE SYSTEMIC EFFECTS
Source text: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。